3D Medicines Completes Early Enrollment in Phase III Trial of Envafolimab for Neoadjuvant/Adjuvant Treatment of Resectable NSCLC 1
3D Medicines Inc. Announces Early Completion of Phase III En...
Sign in to continue:
3D Medicines Inc. Announces Early Completion of Phase III En...
PepGen Inc. Announces Promising Clinical Data for PGN-EDODM1...
Universal Health Services, Inc. - Executive Departure and 8-...
Aebi Schmidt Holding AG Annual Meeting – Key Investor Takeaw...
Badger Meter Unveils Growth Blueprint at 2026 Investor Day: ...
GlobalTech Corp Q1 2026 Earnings: Revenue Soars, Losses Wide...
Rigetti Computing Signs LOI with U.S. Government for Quantum...
HawkEye 360, Inc. 8-K Financial Report Analysis HawkEye ...
Constellation Brands Announces Election of Morgan Flatley to...
Cognition Therapeutics Advances Zervimesine (CT1812) Program...